SEC Form 4 · accession 0000886163-15-000072
LIGAND PHARMACEUTICALS INC · LGND
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Matthew W Foehr
Officer — President and COO
Period of report
Jun 26, 2015
Accepted (ET)
Jun 30, 2015 · 5:39 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000886163
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 26, 2015 | M | 12,500 | $9.97 | A | 82,628 | D | |
| Common StockF1 | Jun 26, 2015 | S | 12,500 | $100.97 | D | 70,128 | D | |
| Common Stock | Jun 29, 2015 | M | 2,500 | $9.97 | A | 72,628 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1,F2 | $9.97 | Jun 26, 2015 | M | 12,500 | D | — | Apr 18, 2021 | Common Stock | 12,500 | 94,510 | D |
| Employee Stock Option (right to buy)F2 | $9.97 | Jun 29, 2015 | M | 2,500 | D | — | Apr 18, 2021 | Common Stock | 2,500 | 92,010 | D |
Explanation of responses
- F1The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on May 20, 2015, in accordance with Rule 10b5-1.
- F2Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant is 04/18/11.